{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:35:38Z","timestamp":1792510538749,"version":"4.5.0"},"reference-count":23,"publisher":"Massachusetts Medical Society","issue":"6","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2021,2,11]]},"DOI":"10.1056\/nejmoa2023184","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T17:03:18Z","timestamp":1606928598000},"page":"497-511","source":"Crossref","is-referenced-by-count":1959,"title":["Repurposed Antiviral Drugs for Covid-19 \u2014 Interim WHO Solidarity Trial Results"],"prefix":"10.1056","volume":"384","author":[{"name":"WHO Solidarity Trial Consortium","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","unstructured":"World Health Organization. A coordinated global research roadmap: 2019 novel coronavirus. March 2020 (https:\/\/www.who.int\/publications\/m\/item\/a-coordinated-global-research-roadmap)."},{"key":"e_1_3_5_3_2","unstructured":"World Health Organization. R&D blueprint and Covid-19 (https:\/\/www.who.int\/teams\/blueprint\/covid-19)."},{"key":"e_1_3_5_4_2","unstructured":"World Health Organization. An international randomised trial of additional treatments for Covid-19 in hospitalised patients who are all receiving the local standard of care (https:\/\/www.who.int\/publications\/m\/item\/an-international-randomised-trial-of-additional-treatments-for-covid-19-in-hospitalised-patients-who-are-all-receiving-the-local-standard-of-care)."},{"issue":"9","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"e1003252","DOI":"10.1371\/journal.pmed.1003252","article-title":"Covid-19 prevention and treatment: a critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.","volume":"17","author":"White NJ","year":"2020","unstructured":"White NJ, Watson JA, Hoglund RM, Chan XHS, Cheah PY, Tarning J. Covid-19 prevention and treatment: a critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. PLoS Med 2020;17(9):e1003252-e1003252.32881895","journal-title":"PLoS Med"},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.15894097","journal-title":"Lancet"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 \u2014 final report.","volume":"383","author":"Beigel JH","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 \u2014 final report. N Engl J Med 2020;383:1813-1826.32445440","journal-title":"N Engl J Med"},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe Covid-19: a randomised, double-blind, placebo-controlled, multicentre trial.","volume":"395","author":"Wang Y","year":"2020","unstructured":"Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe Covid-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:1569-1578.32423584","journal-title":"Lancet"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate Covid-19: a randomized clinical trial.","volume":"324","author":"Spinner CD","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate Covid-19: a randomized clinical trial. JAMA 2020;324:1048-1057.32821939","journal-title":"JAMA"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19.","volume":"383","author":"Goldman JD","year":"2020","unstructured":"Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020;383:1827-1837.32459919","journal-title":"N Engl J Med"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/bjc.2011.79","article-title":"Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care.","volume":"104","author":"Peto R","year":"2011","unstructured":"Peto R. Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care. Br J Cancer 2011;104:1057-1058.21448174","journal-title":"Br J Cancer"},{"key":"e_1_3_5_12_2","unstructured":"FDA Center for Drug Evaluation and Research. FDA\u2019s approval of Veklury (remdesivir) for the treatment of Covid-19: summary review (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/214787Orig1s000Sumr.pdf)."},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with Covid-19.","volume":"383","author":"Horby P","year":"2020","unstructured":"Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020;383:2030-2040.33031652","journal-title":"N Engl J Med"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir-ritonavir in patients admitted to hospital with Covid-19 (RECOVERY): a randomised, controlled, open-label, platform trial.","volume":"396","author":"RECOVERY Collaborative Group","year":"2020","unstructured":"RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with Covid-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2020;396:1345-1352.33031764","journal-title":"Lancet"},{"key":"e_1_3_5_15_2","unstructured":"Axfors C Schmitt AM Janiaud P et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials. October 22 2020 (https:\/\/www.medrxiv.org\/content\/10.1101\/2020.09.16.20194571v2). preprint."},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19.","volume":"382","author":"Cao B","year":"2020","unstructured":"Cao B, Wang Y, Wen D, et al. A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382:1787-1799.32187464","journal-title":"N Engl J Med"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"104866","DOI":"10.1016\/j.antiviral.2020.104866","article-title":"Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of Covid-19 infection.","volume":"181","author":"Venisse N","year":"2020","unstructured":"Venisse N, Peytavin G, Bouchet S, et al. Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of Covid-19 infection. Antiviral Res 2020;181:104866-104866.32659293","journal-title":"Antiviral Res"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1093\/jac\/dkaa195","article-title":"Lopinavir pharmacokinetics in Covid-19 patients.","volume":"75","author":"Gregoire M","year":"2020","unstructured":"Gregoire M, Le Turnier P, Gaborit BJ, et al. Lopinavir pharmacokinetics in Covid-19 patients. J Antimicrob Chemother 2020;75:2702-2704.32443151","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1089\/10799900050163226","article-title":"Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers.","volume":"20","author":"Buchwalder PA","year":"2000","unstructured":"Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 2000;20:857-866.11054273","journal-title":"J Interferon Cytokine Res"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s13054-020-03048-5","article-title":"Interferon beta-1a for COVID-19: critical importance of the administration route.","volume":"24","author":"Jalkanen J","year":"2020","unstructured":"Jalkanen J, Hollm\u00e9n M, Jalkanen S. Interferon beta-1a for COVID-19: critical importance of the administration route. Crit Care 2020;24:335-335.32532353","journal-title":"Crit Care"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00134-020-06086-3","article-title":"Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung.","volume":"46","author":"Jalkanen J","year":"2020","unstructured":"Jalkanen J, Pettil\u00e4 V, Huttunen T, Hollm\u00e9n M, Jalkanen S. Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. Intensive Care Med 2020;46:1937-1940.32430515","journal-title":"Intensive Care Med"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1128\/MCB.00146-10","article-title":"The type I interferon signaling pathway is a target for glucocorticoid inhibition.","volume":"30","author":"Flammer JR","year":"2010","unstructured":"Flammer JR, Dobrovolna J, Kennedy MA, et al. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol 2010;30:4564-4574.20679482","journal-title":"Mol Cell Biol"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"e_1_3_5_24_2","unstructured":"World Health Organization. Corticosteroids for COVID-19: living guidance 2 September 2020 (https:\/\/apps.who.int\/iris\/handle\/10665\/334125)."}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2023184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:26:15Z","timestamp":1711484775000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2023184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,2,11]]}},"alternative-id":["10.1056\/NEJMoa2023184"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2023184","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.10.15.20209817","asserted-by":"object"}]},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]}}}